Education
About Us
Working with TipRanks
Follow Us
Sun Pharma Advanced Research Co. Ltd. (IN:SPARC)
:SPARC
SPARC Stock Chart & Stats
₹135.70
-₹2.58(-1.32%)
At close: 4:00 PM EST
₹135.70
-₹2.58(-1.32%)
Day’s Range― - ―
52-Week Range₹116.65 - ₹204.25
Previous CloseN/A
Volume383.41K
Average Volume (3M)24.00K
Market Cap
₹40.31B
Enterprise Value₹44.52B
Total Cash (Recent Filing)₹19.64M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta1.74
Next Earnings
May 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.48
Shares Outstanding324,521,580
10 Day Avg. Volume27,089
30 Day Avg. Volume24,005
Financial Highlights & Ratios
PEG Ratio1.20
Price to Book (P/B)-21.89
Price to Sales (P/S)66.17
P/FCF Ratio-12.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Partner-driven Monetization ModelSPARC's business model monetizes drug candidates via out-licensing and partnerships that deliver upfront, milestone and royalty streams. Structurally this reduces capital intensity per program, lets external partners fund expensive late-stage work, and creates durable, event-driven revenue sources if candidates advance.
Focused R&D On Novel Specialty TherapeuticsA concentrated focus on novel and specialty therapeutics builds specialized scientific expertise and proprietary assets that are harder for generic competitors to replicate. Over months this creates a durable competitive moat in select therapy areas and enhances licensing leverage versus broad, undifferentiated developers.
Improving Cash ManagementReported improvements in cash management show management is taking steps to curb burn and extend runway. If sustained, tighter cash controls reduce near-term financing needs, preserve value for partners, and increase the firm’s ability to fund critical development milestones without immediate dilutive financing.
Bears Say
Negative Shareholders' Equity And High LeverageNegative equity and significant leverage materially weaken financial flexibility, raising insolvency and covenant risks. Over the medium term this constrains the firm's ability to underwrite expensive clinical programs, negotiate favorable partner terms, or absorb setbacks without costly external financing.
Persistent Negative Operating And Free Cash FlowSustained negative operating and free cash flow forces recurring reliance on external funding, increasing dilution or interest burdens. Structurally this limits the company's ability to self-fund development, elevates execution risk for multi-year trials, and reduces resilience to missed milestones.
Sustained Unprofitability And Declining RevenueOngoing negative EBIT and net losses alongside revenue declines indicate the core business is not yet generating sustainable returns. Over several months this undermines bargaining power with partners, increases dependence on milestone-triggered cash events, and signals persistent operational or commercial weaknesses.
Sun Pharma Advanced Research Co. Ltd. News
SPARC FAQ
What was Sun Pharma Advanced Research Co. Ltd.’s price range in the past 12 months?
Sun Pharma Advanced Research Co. Ltd. lowest stock price was ₹116.65 and its highest was ₹204.25 in the past 12 months.
What is Sun Pharma Advanced Research Co. Ltd.’s market cap?
Sun Pharma Advanced Research Co. Ltd.’s market cap is ₹40.31B.
When is Sun Pharma Advanced Research Co. Ltd.’s upcoming earnings report date?
Sun Pharma Advanced Research Co. Ltd.’s upcoming earnings report date is May 25, 2026 which is in 75 days.
How were Sun Pharma Advanced Research Co. Ltd.’s earnings last quarter?
Sun Pharma Advanced Research Co. Ltd. released its earnings results on Feb 09, 2026. The company reported -₹2.478 earnings per share for the quarter, missing the consensus estimate of N/A by -₹2.478.
Is Sun Pharma Advanced Research Co. Ltd. overvalued?
According to Wall Street analysts Sun Pharma Advanced Research Co. Ltd.’s price is currently Overvalued.
Does Sun Pharma Advanced Research Co. Ltd. pay dividends?
Sun Pharma Advanced Research Co. Ltd. does not currently pay dividends.
What is Sun Pharma Advanced Research Co. Ltd.’s EPS estimate?
Sun Pharma Advanced Research Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sun Pharma Advanced Research Co. Ltd. have?
Sun Pharma Advanced Research Co. Ltd. has 324,521,580 shares outstanding.
What happened to Sun Pharma Advanced Research Co. Ltd.’s price movement after its last earnings report?
Sun Pharma Advanced Research Co. Ltd. reported an EPS of -₹2.478 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.755%.
Which hedge fund is a major shareholder of Sun Pharma Advanced Research Co. Ltd.?
Currently, no hedge funds are holding shares in IN:SPARC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sun Pharma Advanced Research Co. Ltd.
Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, and dermatology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders; and HitGen Ltd. to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited
Technical Analysis
Aarti Drugs Limited
―
RPG Life Sciences Limited
―
Supriya Lifescience Limited
―
Suven Life Sciences Limited
―
Thyrocare Technologies Ltd
―